Wave stock shaken, analysts stirred by 007’s obesity phase I

AI Briefing

• – Wave Life Sciences Inc. rolled out phase I data for WVE-007, a potential obesity treatment, which was met with a negative reaction from investors.
• – The trial showed no significant effects of 250 mg of WVE-007 on weight loss or other obesity-related measures in healthy overweight or obese adults.
• – Analysts expressed disappointment and concerns about the efficacy of WVE-007 in its current dosage.